发现,表征和优化D3多巴胺受体的新型阳性体调节器-对手D3多巴胺受体
Amy E Moritz1, Feijun Wang2, Nora S Madaras1
1Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States.
研究人员确定了新的多巴胺D3受体 (D3R) 抗剂,具有独特的阳性全调节剂-抗剂活性. 化合物6a和10aa作为研究工具和神经精神疾病的潜在治疗方法具有前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 多巴胺D3受体 (D3R) 是神经精神疾病的关键标.
- 新的D3R选择性抗剂是治疗开发所需的.
研究的目的:
- 为了识别新的D3R选择性对抗剂支架.
- 描述已识别的化合物的独特的全调节剂-对抗剂活性.
- 评估新型D3R抗剂的治疗潜力.
主要方法:
- 使用β-逮捕素招募试验进行高通量选.
- 代药物化学用于合成和表征类似物.
- 在小鼠体内测试D3R选择性,功效 (β-停止蛋白招募,G蛋白激活) 和体内药物动力学研究.
主要成果:
- 确定了MLS6357作为一种化合物,具有前所未有的D3R选择性和阳性全调节器 (PAM) 抗活性.
- 合成了137种类似物,其中6a和10aa化合物在D3R强度和选择性方面显著改善.
- 化合物6a和10aa重复了PAM-对手的形状,并在小鼠中显示出有利的药理动力学.
结论:
- 确定了具有独特PAM-对抗剂特性的新型D3R选择性对抗剂支架.
- 化合物6a和10aa代表了研究工具和治疗神经精神疾病的治疗开发的有希望的线索,包括物质使用障碍.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
相关概念视频
Antipsychotic Drugs: Typical and Atypical Agents
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Drug Discovery: Overview
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Drugs Affecting Neurotransmitter Synthesis
